Zobrazeno 1 - 10
of 62
pro vyhledávání: '"S. Claiborne Johnston"'
Autor:
Anxin, Wang, Xia, Meng, Xue, Tian, S Claiborne, Johnston, Hao, Li, Philip M, Bath, Yingting, Zuo, Xuewei, Xie, Jing, Jing, Jinxi, Lin, Yilong, Wang, Xingquan, Zhao, Zixiao, Li, Yong, Jiang, Liping, Liu, Feng, Wang, Ying, Li, Jingyao, Liu, Yongjun, Wang
Publikováno v:
Annals of Neurology. 91:380-388
This study was undertaken to identify the risk of bleeding events and potential risk factors within 90 days in patients who carried CYP2C19 loss-of-function alleles and received dual antiplatelet therapy after minor stroke or transient ischemic attac
Autor:
Anxin, Wang, Xuewei, Xie, Xue, Tian, S Claiborne, Johnston, Hao, Li, Philip M, Bath, Yingting, Zuo, Jing, Jing, Jinxi, Lin, Yilong, Wang, Xingquan, Zhao, Zixiao, Li, Yong, Jiang, Liping, Liu, Xia, Meng, Yongjun, Wang
Publikováno v:
Annals of internal medicine. 175(11)
Evidence on the risk-benefit ratio of dual antiplatelet therapies among patients with stroke and impaired renal function is limited and inconsistent.To investigate the effect of renal function on the efficacy and safety of ticagrelor-aspirin versus c
Autor:
Xinmiao Zhang, Jing Jing, Xingquan Zhao, Liping Liu, Anxin Wang, Yuesong Pan, David Wang, S. Claiborne Johnston, Yilong Wang, Yongjun Wang, Xia Meng
Publikováno v:
Neurological research. 44(11)
Previous studies demonstrated that discontinuation of clopidogrel in patients after ACS was associated with a rebound increase in risk of recurrent events. In this study, we aimed to investigate the rebound effect after discontinuation of clopidogrel
Autor:
Anxin, Wang, Xia, Meng, Xue, Tian, S Claiborne, Johnston, Hao, Li, Philip M, Bath, Yingting, Zuo, Xuewei, Xie, Jing, Jing, Jinxi, Lin, Yilong, Wang, Xingquan, Zhao, Zixiao, Li, Yong, Jiang, Liping, Liu, Feng, Wang, Yanxia, Wang, Panbing, Huang, Guofang, Chen, Yongjun, Wang
Publikováno v:
Stroke. 53(9)
Background: Hypertension is a risk factor of poor stroke outcomes and associated with antiplatelet resistance. This study aimed to explore the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin in patients with different hypertensio
Autor:
John C Chaloupka, Allan J. Fox, Alain Bonafe, Cameron G. McDougall, Donatella Tampieri, Christopher F. Dowd, Juan Carlos Vazquez Suarez, Ajay K. Wakhloo, Anil Gholkar, Javier Romero, Aquilla S Turk, Steven W. Hetts, Stanley L. Barnwell, S. Claiborne Johnston
Publikováno v:
Journal of NeuroInterventional Surgery. 13:930-934
BackgroundNo randomized trial of intracranial aneurysm coiling has compared long-term efficacy of polymer-modified coils to bare metal coils (BMCs). We report 5-year results comparing Matrix2 coils to BMCs. The primary objective was to compare the ra
Autor:
Yuesong Pan, Xia Meng, Aoming Jin, S. Claiborne Johnston, Hao Li, Philip M. Bath, Xuewei Xie, Jing Jing, Jinxi Lin, Yilong Wang, Xingquan Zhao, Zixiao Li, Yong Jiang, Liping Liu, Hongqin Yang, Jiwei Cheng, Zhimin Wang, Yongjun Wang
Publikováno v:
JAMA Neurology. 79:739
Dual antiplatelet therapy (DAPT) with ticagrelor and aspirin has been found to be effective for secondary prevention after minor ischemic stroke or transient ischemic attack (TIA) in individuals who carry CYP2C19 loss-of-function (LOF) alleles; howev
Autor:
Yuesong Pan, Xia Meng, Weiqi Chen, Jing Jing, Jinxi Lin, Yong Jiang, S Claiborne Johnston, Philip M Bath, Qiang Dong, An-Ding Xu, Hao Li, Yongjun Wang
Publikováno v:
Stroke and Vascular Neurology. 7:e001480
BackgroundIndobufen can reversibly inhibit platelet aggregation and showed to be effective in the treatment of ischaemic heart and peripheral vascular diseases. However, it is unclear whether indobufen is an alternative antiplatelet agent for treatme
Autor:
Sven Nylander, Anders Himmelmann, Joachim Röther, Per Ladenvall, S. Claiborne Johnston, Scott R. Evans, Carlos A. Molina, Marianne Jahreskog, Yongjun Wang, Mikael Knutsson, Hans Denison, Maria Aunes, Pierre Amarenco, Stefan James
Publikováno v:
Stroke
Supplemental Digital Content is available in the text.
Background and Purpose: In patients with acute mild-moderate ischemic stroke or high-risk transient ischemic attack, the THALES trial (Acute Stroke or Transient Ischemic Attack Treated With
Background and Purpose: In patients with acute mild-moderate ischemic stroke or high-risk transient ischemic attack, the THALES trial (Acute Stroke or Transient Ischemic Attack Treated With
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::663a1e9b9310db37ea05b9d95f2298aa
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-458771
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-458771
Autor:
Pierre Amarenco, Ks Lawrence Wong, Gregory W. Albers, Per Ladenvall, Philip M.W. Bath, Kazuo Minematsu, Hans Denison, J. Donald Easton, Jenny Jonasson, Scott R. Evans, S. Claiborne Johnston, Yongjun Wang, Carlos A. Molina, Mikael Knutsson
Publikováno v:
Clinical trials (London, England). 17(6)
Background/Aims: Standard approaches to trial design and analyses can be inefficient and non-pragmatic. Failure to consider a range of outcomes impedes evidence-based interpretation and reduces power. Traditional approaches synthesizing information o
Autor:
Ronald L. Walton, Karla G. Zurita, William G. Barsan, Luca P. Farrugia, Owen A. Ross, J. Donald Easton, Jordan J. Elm, James F. Meschia, Mary Farrant, Brett Cucchiara, Nina T. Gentile, S. Claiborne Johnston, William J. Meurer, Michael A. Ross, Fadi Nahab, Anthony S. Kim, Marilou Ching, Anne S. Lindblad
Publikováno v:
Stroke
Stroke, vol 51, iss 7
Stroke, vol 51, iss 7
Background and Purpose: Clopidogrel is an antiplatelet drug that is metabolized to its active form by the CYP2C19 enzyme. The CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) found a significant interact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::105b90bd5b4ec1d00dd454e983903d5c
https://europepmc.org/articles/PMC9523583/
https://europepmc.org/articles/PMC9523583/